These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34675504)

  • 1. Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England.
    Sansbury LB; Wood RP; Anley GA; Nam Y; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2021; 16():2795-2808. PubMed ID: 34675504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.
    Beeh KM; Rothnie KJ; Claussen J; Hardtstock F; Knapp RK; Wilke T; Czira A; Compton C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2024; 19():945-956. PubMed ID: 38646606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
    Bogart M; Bengtson LGS; Johnson MG; Bunner SH; Gronroos NN; DiRocco KK
    Int J Chron Obstruct Pulmon Dis; 2024; 19():97-110. PubMed ID: 38226396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea.
    Lee CH; Kim MS; Yeo SH; Rhee CK; Park HW; Yang BR; Lee J; Cho EY; Xu X; Navarro Rojas AA; Shantakumar S; Milea D; Choi NK
    Respir Res; 2022 Sep; 23(1):231. PubMed ID: 36064539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain.
    Alcázar-Navarrete B; Jamart L; Sánchez-Covisa J; Juárez M; Graefenhain R; Sicras-Mainar A
    Chest; 2022 Nov; 162(5):1017-1029. PubMed ID: 35787391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting.
    Halpin DMG; Rothnie KJ; Banks V; Czira A; Compton C; Wood R; Tritton T; Massey O; Wild R; Snowise N; Nikitin K; Sharma R; Ismaila AS; Vogelmeier CF
    Int J Chron Obstruct Pulmon Dis; 2022; 17():2417-2429. PubMed ID: 36185170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study.
    Rothnie KJ; Wood RP; Czira A; Banks VL; Camidge LJ; Massey OKI; Seif M; Compton C; Sharma R; Halpin DMG; Ismaila AS; Vogelmeier CF
    BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38772900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Treatment Patterns of Multiple-Inhaler Triple Therapy Among Patients with Chronic Obstructive Pulmonary Disease in UK General Practice.
    Sansbury LB; Bains C; Lipson DA; Ismaila AS; Landis SH
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1255-1264. PubMed ID: 33986594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β
    Requena G; Banks V; Czira A; Wood R; Tritton T; Wild R; Compton C; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():231-245. PubMed ID: 36908830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.
    Ismaila AS; Rothnie KJ; Wood RP; Banks VL; Camidge LJ; Czira A; Compton C; Sharma R; Millard SN; Massey O; Halpin DMG
    Respir Res; 2023 Sep; 24(1):229. PubMed ID: 37749551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Real-World Analysis of Treatment Patterns and Clinical Characteristics Among Patients with COPD Who Initiated Multiple-Inhaler Triple Therapy in New Zealand.
    Xu X; Milea D; Navarro Rojas AA; Braganza A; Holbrook T; Marett B; Young R; Scott RJ; Gribben B
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1835-1850. PubMed ID: 34177262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study.
    Vogelmeier CF; Beeh KM; Schultze M; Kossack N; Richter LM; Claussen J; Compton C; Noorduyn SG; Ismaila AS; Requena G
    Int J Chron Obstruct Pulmon Dis; 2024; 19():1835-1848. PubMed ID: 39140078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study.
    Czira A; Akiyama S; Ishii T; Wood RP; Camidge LJ; Wallis H; Jennison T; Wild RAC; Yarita M; Hashimoto K; Rothnie KJ; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2023; 18():2933-2953. PubMed ID: 38089540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population.
    Bogart M; Stanford RH; Laliberté F; Germain G; Wu JW; Duh MS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():343-352. PubMed ID: 30863037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical burden of illness among patients with severe eosinophilic COPD.
    Müllerová H; Meeraus WH; Galkin DV; Albers FC; Landis SH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():741-755. PubMed ID: 31114180
    [No Abstract]   [Full Text] [Related]  

  • 17. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
    Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
    Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
    Mannino D; Bogart M; Germain G; Huang SP; Ismaila AS; Laliberté F; Jung Y; MacKnight SD; Stiegler MA; Duh MS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():491-504. PubMed ID: 35281476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β
    Requena G; Banks V; Czira A; Wood R; Tritton T; Wild R; Compton C; Duarte M; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():1781-1795. PubMed ID: 35983168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exacerbations and health care resource use among patients with COPD in relation to blood eosinophil counts.
    Müllerová H; Hahn B; Simard EP; Mu G; Hatipoğlu U
    Int J Chron Obstruct Pulmon Dis; 2019; 14():683-692. PubMed ID: 30962682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.